The story
Boston Scientific expands pain management portfolio with $533m Nalu Medical buy
The acquisition is valued at approximately $533 million in upfront cash for the remaining equity not already owned by Boston Scientific. Boston Scientific has maintained a strategic investment relationship with Nalu Medical since 2017, positioning this acquisition as a natural progression of their existing partnership.
"Boston Scientific has entered into a definitive agreement with Nalu Medical, a privately held medical technology company focused on developing minimally invasive solutions for patients with chronic pain. We expect the addition of this technology to further expand our interventional pain portfolio by addressing the unmet needs of a broader patient population with peripheral nerve pain," a spokesperson for Boston Scientific told BioXconomy.
https://www.bioxconomy.com/partnering/boston-scientific-expands-pain-management-portfolio-with-533m-nalu-medical-buy